The UK and US have signed a key bilateral deal that will guarantee no import taxes on British medicine products entering the American market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost expenditure on drugs through the National Health Service (NHS). This move guarantees that import taxes on these vital goods will stay at nothing for a timeframe of 36 months.
This agreement comes after previous warnings to significantly raise duties on patented drug products, with increases discussed reaching one hundred percent.
"This arrangement between the United Kingdom bolsters the global environment for cutting-edge drugs and establishes long-overdue fairness to U.S.–U.K. pharmaceutical trade," an announcement declared.
Trade Importance
Drugs are one of the Britain's biggest export categories to the United States, which is clearly the largest market for major companies like GSK and AstraZeneca.
Export figures show that in the 12 months leading up to last September, the UK sold medicines worth £11.1bn to the US. This amount represented nearly one-fifth of total UK exports in that timeframe.
"This guarantee protects employment, increases capital expenditure and facilitates the UK to become a worldwide center for biotech and pharma," a government official commented.
Detailed British Pledges
The pact involves several notable commitments from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a goal to raise overall public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The amount drug companies must pay back to the NHS to control costs will be limited at 15%. Previously, repayments topped twenty percent.
Broader Context
This agreement takes place against a ongoing tension between the sector and the ministers over medicine costs and approval rates.
This friction were heightened by assertions that US patients were paying a premium for the equivalent treatments than patients in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been announced toward US facilities.
A senior figure acknowledged that the NHS had to invest a greater share on drugs, noting that its spending on drugs had declined as a share of its overall budget over the previous ten-year period.
